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INTRODUCTION 
 INTRODUCTION 
Breast carcinoma is the second most common type of malignancy 
diagnosed in female’s next onlyto cervical carcinomaworldwide. In 
majority of the developedcountriesit is the most frequently encountered 
malignancy and one of the major causes for cancer related deaths
1
. Breast 
carcinoma has been extensively studied upon in the modern medicine era 
and with the availability of vast evidence based data and literature various 
treatment modalities have been introduced to treat this life threatening 
disease. 
Majority of the breast carcinomas are usually asymptomatic and 
the usual mode of presentation is an incidental palpable lump or pain and 
rarely, they present with nipple discharge and skin changes
2
. Breast 
carcinomas have varying levels of invasion and aggressiveness 
irrespective of the duration and the metastatic symptom could be the 
presenting complaint in a few. Even though extensive screening programs 
and clinical tests are available for early detection of this disease the 
turnover and outcome still remains poor in developing countries. There is 
a lack of self-awareness of this life threatening malignancy in our 
country. 
The general approach in case of breast carcinoma is by triple 
assessment test combining the clinical finding with that of the 
radiological and pathological correlation remains as a standard guideline 
for breast carcinoma. The categorisation is based upon the triple 
assessment test
3
. Liver function assessment, X-Ray, ultrasonography and 
bone scan aid in staging the disease. 
Histo-pathological correlation along with immunohistochemistry 
analysis has introduced another modality of treatment with hormones. 
The usual routine of management in breast carcinoma is with surgery, 
radiotherapy and chemotherapy depending on the stage of the disease
4
. 
Though each modality of treatment has its own pros and cons, combined 
approach is the therapy of choice leading to less toxic therapy with a 
good outcome and better prognosis. 
Breast carcinoma management is reaching new heights with its vast 
research interest and data availability. Numerous centres throughout the 
world are promoting screening programmes and self-examination test to 
detect the disease as early as possible  
In this study we have concluded our experience and interest with 
the breast carcinomas and its immunohistochemistry analysis in different 
stages of disease process and we aid to improve the current knowledge 
with our encounter with this life threatening disease. 
  
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 AIM OF THE STUDY 
 
 
 
 
• To analyze the Estrogen/ Progesterone/ Human epidermal growth 
factor 2 receptor status in breast carcinomas and comparing them 
with that of the staging 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
  
REVIEW OF LITERATURE 
History of Breast carcinoma: 
The first documented historical note about breast carcinoma is by 
the Egyptians in 1600 BC which is titled as ‘CASE 45- INSTRUCTIONS 
CONCERNING TUMOURS ON HIS BREAST’ which elaborates that 
the tumour is bulging and cold and this ailment has no treatment
4,5
. 
Aurelius celsus in 30 AD wrote ‘De Medicina’ which contains the 
description of a breast cancer.He described it as an irregularly fixed 
swelling with dilated veins and ulceration, he also categorised them into 4 
varieties. The greek are credited for their first ever surgical approach to 
breast carcinoma by applying heat to the tumour and escharing
5
 it.In the 
renaissance period the amputation of the breast was considered to be the 
treatment of choice for the breast carcinoma and they even suggested that 
the axillary lump is most likely a sequel of breast tumour. 
In the 18
th
 century Henri francois le dran from france suggested 
that in early stages breast carcinoma is a localised disease process and 
later it spreads to the lymphatics
5
.In 1829 the term ‘metastasis’ was 
introduced by Dr.Joseph reclaimer. In 1874 Paget published a paper on 
the ‘disease of the mammary areola a preceding cancer of the mammary 
gland’ which described the involvement of nipple with eczematous 
changes along with malignant lactiferous ducts (Paget’s disease of the 
nipple) 
\           Undoubtedly the 20
th
 century can be called the revolutionary 
period in the history of breast carcinoma with its pioneers and modern 
medical and surgical practice
6
. William Halsted proposed that the 
specimen should be removed in one piece as he suggested that the 
manipulation would increase the risk of spread and introduced the 
Radical mastectomy which was practised without argument for more than 
70 year. Later, Patey and Dyson introduced the approach of modified 
radical mastectomy. Dr. Donald .L Morton introduced the concept of 
sentinel lymph node biopsy revolutionizing the indication and staging 
work up of breast carcinomas
6
. 
The introduction of radiotherapy as a modality of treatment of 
breast carcinomas was popularised by Dr.William Stone and he claimed 
that radiotherapy is superior to surgery in case of advanced malignancy
6
. 
Bernard Fischer through his dedicated work on breast cancer explained 
the concept of systemic disease of this tumour and suggested that breast 
carcinoma is a systemic disease and requires multimodality approach
7
. 
The hormonal receptors namely the estrogen and progesterone 
were demonstrated in 1970’s  and since 1980’s tamoxifen has been used 
as to treat breast carcinomas. In late 20
th
 century, several studies revealed 
an equal benefit with both neo adjuvant as well as adjuvant chemotherapy 
regimens. 
The mammogram patterns of all breast carcinoma patients were 
studied for a decade at the Philadelphia institute and their accuracy in 
diagnosis had been published
7
. Later, in 1962 Dr.Egan introduced the 
views of imaging and since 1970’s mammogram is considered as an 
important tool in diagnosis of breast carcinoma
7
. 
 
Date Reconstructive procedure 
1896 Latissimus dorsi flap 
1900 Skin grafts 
1958 Harvested skin grafts with motorised brown dermatome 
1960s Tubed skin flaps 
1964 Silicone breast implants 
1970s Myocutaneous flaps 
1982 TRAM flap 
The breast reconstruction procedures, have been modified 
concurrently with advent of new techniques and implants and has a good 
outcome for a postsurgical patients psychologically as well as 
aesthetically
8
. 
TNM staging was proposed in 1944 and is on standard practise 
since then. In the late 20
th
 century the identification of BRCA1 and 
BRCA 2 is promising and genetic based therapies are awaited to treat this 
disease
9
. 
  
Anatomy of the Breast: 
The breast tissue is embryologically derived and matures as a 
modified sweat gland. They are located within the ‘milk line’ which 
extends from the axilla upto the inguinal region. During the fertile period 
owing to the ovarian hormone synthesis structural changes occur and post 
menopausally
11
, they involute and diminish in structural volume, contour 
and form due to changes in hormonal levels. 
 
ANATOMICAL LOCATION AND EXTENT OF THE BREAST 
  
A mature breast extends from the second to seventh rib vertically 
and horizontally from the sternal border upto the anterior or mid axillary 
line
11
.The ‘axillary tail of spence’ is a continuation of breast in to the 
axilla. The upper outer quadrant is voluminous compared to other 
quadrants. They rest upon the pectoralis major, serratus anterior and 
external oblique muscle
12
. 
Each breast consists of 15 to 20 tubuloalveolar glandular structures 
supported by fibrous connective tissue and adipose tissue.They do not 
possess a capsule but the gravitational and longitudinally support is 
provided by the extension of connective tissue inbetween the lobes and 
lobules. 
A retromammary bursa is formed by the fusion of the fascia of the 
breast with that of the pectoralis muscle which makes it mobile over the 
chest wall. The coopers ligament is a thickened fibrous connective tissue 
travelling from the dermis to the deep layer of the superficial fascia and is 
responsible for the contour of the breast
11
. 
The axilla consists of a pyramidal compartment situated between 
the thoracic cavity and the upper limb. It communicates with the posterior 
triangle through the cervicoaxillary canal
12
. The anterior wall is formed 
by the pectoralis major and minor muscle, posteriorly by the 
subscapularis, teres major and latissimus dorsi. Laterally by the bicipetal 
groove and medially by the serratus anterior. The pectoralis major is 
covered by the pectoral fascia whereas the pectoralis minor and 
subclavius is covered by the clavipectoral fascia or costocoracoid fascia 
extending from the axilla to the clavicle.Thepectoralis minor divides the 
axillary artery into three segments as per their location – medial ,posterior 
and lateral to the pectoralis minor muscle
11,12
.The axillary artery is in 
close continuity with the brachial plexus and the divisions are named as 
per their relation to the artery. 
There are three nerves which are of surgical importance namely the 
long thoracic nerve which supplies the serratus anterior and runs along 
the medial border of the axilla through the cervicoaxillary canal. 
Accidental injury to it causes winging of scapula. The other nerve is the 
thoracodorsal nerve which originates from posterior cord of brachial 
plexus and supplies the latissimus dorsi muscle and accidental division 
causes motor dysfunction and results in atrophy and further manipulation 
for myocutaneous flaps are not feasible
12
. The intercostobrachial nerve 
provides sensation to the apex and lateral axilla. 
The main blood supply to the breast is by the internal mammary 
artery, posterior intercostal artery and branches of the axillary artery
11
. 
The thoracodorsal branch from the subscapular artery is of surgical 
importance as it may cause significant bleeding during axillary dissection 
when severed. The venous drainage of the breast is mainly by the internal 
mammary vein, tributaries of the axillary vein and the posterior 
intercostal vein. The posterior intercostal vein is in close proximity with 
the batson’s venous plexus and accounts for the vertebral, skull and brain 
metastases
12
.The breast has its innervation from the intercostal and 
intercostobrachial nerves and its branches which include the lateral and 
medial mammary branches. 
 
PICTURE SHOWING THE ARTERIAL AND VENOUS SUPPLY OF THE BREAST 
The lymphatic drainage of the breast is predominantly through the 
axillary group of lymph nodes, which consists of six groups of lymph 
node at three anastamotic sites
11,12
. They include the lateral, anterior, 
posterior, central, apical and interpectoral group of lymph nodes. The 
lymph nodes are categorised as per their relationship with the pectoralis 
minor as level I, II and III which lies lateral, behind and medial to it 
respectively
13
.Dr.Sampson Hadley was credited for his recognition of 
internal mammary lymph nodes and his theory of metastatic spread 
through them to the thoracic duct. 
 
LYMPHATIC DRAINAGE OF THE BREAST 
 
Almost 75% of lymphatic drainage of the breast is through the 
axillary lymph node and the rest 25% by the internal mammary, 
intercostal and the diaphragmatic lymph node
13
. Surgically this drainage 
pattern is significant as it forms the pillar for the development of sentinel 
lymph node biopsy technique. However there is no proven exact pathway 
of lymphatic drainage and chances to miss a positive lymph node is 
highly possible. This is considered to be one of the biggest drawbacks of 
sentinel lymph node biopsy
13
. 
  
Diagnostic approach in breast carcinomas: 
The gold standard diagnostic approach in breast carcinoma till 
date
14
 is the triple assessment test which includes 
• History and examination 
• Imaging 
• Tissue/FNAC 
 
 
 
 
 
History and physical examination: 
The key points in the history should be stressed upon in detail with 
a patient presenting with breast pathology. They usually present with a 
palpable lump / pain / discharge / nipple retraction, however 60% of the 
patient with breast carcinoma are asymptomatic at early stages
14
. Past 
history of any gynaecological malignancies, previous breast surgeries and 
irradiation should be enquired in detail. Family history of breast 
carcinomas increases the risk of developing breast malignancy by 
fivefold
15
. There are several proven risk factorsfor development of breast 
carcinoma and all of them are to elaborately taken into consideration in 
case of a suspected breast cancer. They include the following. 
• Female gender 
• Increasing age 
• Family and personal history of breast cancer 
• Previous breast biopsy 
- Proliferative breast disease without atypia 
- Atypical hyperplasia 
- Lobular carcinoma in situ 
• Previous thoracic irradiation 
• Endocrine risk factors 
- early menarche 
- Late menopause 
- Late or nulliparity 
- Long term hormonal therapy 
• Lifestyle factors 
- Alcohol 
- Obesity  
• Genetic factors 
- BRCA 1 & 2 
- Ataxia telangiectasia 
- Li-fraumeni syndrome 
- Cowden syndrome     
In physical examination the size and location of tumour, extent, 
fixity, skin involvement helps in concluding the ‘T’ stage of the disease. 
Careful examination of all groups of lymph node is mandatory in breast 
carcinoma and the opposite breast and nipple examination is of utmost 
importance. The single most important prognostic factor in breast 
carcinoma is considered to be the lymph node status and the ‘N’ stage of 
the disease is ascertained based on this examination. Systemic 
examination is warranted as breast malignancy is considered to be 
systemic disease and metastasis should be ruled out by both clinical 
examination as well as investigations to ascertain the ‘M’ stage of the 
disease and to decide upon the modality of management. 
The breast malignancy is universally classified by the AJCC, by a 
combination of the Tumour size, nodal status and metastatic disease into 
TNM staging. The TNM staging is the same for clinical as well as the 
pathological except for sub categorising them according to the 
pathological findings and are denoted by subsets. Depending on the TNM 
staging the breast malignancy is further classified into four different 
stages using a combination probability of the same. For management and 
prognostic purposes the staging is further divided into early breast 
carcinoma, loco-regionally advanced breast cancer and metastatic 
carcinoma. They include the following 
 
 
 
 
  
TNM STAGING
15 
Primary tumour (T) 
TX   -  Tumour cannot be assessed 
T0    -  No evidence of primary tumour 
Tis    - Carcinoma in situ  
T1    -  Tumour less than 2 cm in greater dimension 
        T1mic   -   micro invasion 0.1cm or less 
        T1a       -   more than 0.1 but less than 0.5cm 
        T1b       -   more than 0.5cm but less than 1cm 
        T1c       -   more than 1cm but less than 2cm 
T2    -  Tumour more than 2 cm but less than 5 cm in greater dimension 
T3    -  Tumour more than 5 cm in greater dimension 
T4    -  Tumour of any size with direct extension into skin or chest wall 
        T4a    -  extension to chest wall 
        T4b    -  edema(peau’d orange) or ulceration or satellite nodules 
        T4c    - Both T4a and T4b 
        T4d    - Inflammatory carcinoma 
Regional lymph nodes (N) 
NX  -  regional lymph nodes cannot be assessed 
N0  -  No regional lymph node metastasis 
N1  -  Metastasis to ipsilateral mobile lymph node 
N2  -  Ipsilateral fixed lymph nodes 
N3  -  Metastasis to ipsilateral internal mammary lymph node 
 
Distant metastasis 
MX  -  Distant metastasis cannot be assessed 
M0  -  No distant metastasis 
M1  -  Distant metastasis (ipsilateral supraclavicular lymph node is 
included)  
 
 
 
 
 
TNM Staging 
Modified AJCC cancer staging of breast carcinoma 
Stage 0 
 
Tis 
 
N0 
 
M0 
 
Stage I 
 
T1a 
 
 
N0 
 
M0 
 
Stage II A 
 
T0 
T1a 
T2 
N1 
N1 
N0 
M0 
M0 
M0 
Stage II B T2 
T3 
N1 
N0 
M0 
M0 
Stage III A 
 
 
 
 
T0 
T1a 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
M0 
M0 
M0 
M0 
M0 
Stage  III B 
 
 
T4 
T4 
T4 
N0 
N1 
N2 
M0 
M0 
M0 
Stage III C Any T N3 M0 
Stage IV Any T Any N M1 
 
• Early breast carcinoma -  Stage I and II A&B 
• Locally advanced breast carcinoma  -  Stage III A,B&C 
• Metastatic breast carcinoma  -  Stage IV 
 
  
Imaging 
Over the past century there had been a vast revolutionary change in 
the field of radiology implementing new techniques and aiding accurate 
diagnosis in breast carcinomas. The imaging modalities in breast 
carcinoma include 
• Mammogram 
• Ultrasound 
• Ductography 
• CT/MRI 
• PET CT/Bone scan 
 
Mammography 
In asymptomatic patient screening mammogram is used to detect 
breast lesions if they are not clinically conclusive or in a patient with 
nipple retraction or nipple discharge without any palpable pathology or in 
a patient who had undergone breast conservative surgery for previous 
malignancy.  
 
               Mammogram consists of two basic views the craniocaudal view 
and the medio-lateral-oblique view. They are checked for 
asymmetry,calcifications, masses or architectural distortions, they either 
present individually or in a combination of the above
16
. In case of 
margins they are described as per their shape (round, oval, lobular, 
irregular) and margins(circumscribed, microlobulated, obscured, ill 
defined, spiculated)
16
. Calcifications alone do not suggest the lesion to be 
malignant as they coexist in normal and benign conditions of the breast. 
             The American college of radiology has developed the Breast 
imaging reporting and data system (BIRADS) for classifying breast 
lesions which is as follows
16 
0 Needs additional image evaluation 
1 Negative 
2 Benign finding 
3 Probably benign finding 
4 Suspicious of malignancy 
5 Highly suggestive of carcinoma 
6 Known carcinoma 
 
 
Ultrasound 
A 7MHz linear transducer is the minimum frequency to image 
breast lesion. Though mammogram is not the ideal choice of 
investigation for breast carcinoma it is an excellent adjunct in evaluation 
of breast cancer when combined with mammogram and few 
interventional procedures. The accuracy of ultrasound is 100% in breast 
cysts
17
. The malignant features of lesion in ultrasonography include 
irregular margins, hypoechoic, posterior acoustic shadowing and vertical 
growth appearance
17
. 
Ductography 
Nipple discharge and retraction can be evaluated with ductography 
in which a contrast is injected in to the duct to identify the filling 
defect
16,6
. But this modality of investigation is not very specific nor 
sensitive for malignancy 
MRI 
Though mammogram is the considered as the ‘gold standard’ for 
breast imaging, MRI is slowly gaining importance in breast malignancy 
as it penetrates and density and micromatic changes can be picked up by 
the MRI.1.5 tesla magnet or greater is to be used in imaging and 
gadolinium is the contrast of choice
18
. The MRI shows post contrast 
enhancement of malignant lesion 
PET CT 
PET CT is used in metastatic work up of breast carcinoma. It traces 
the uptake of FDG polymer by the tumour cells
18
. The limitation of this 
imaging test is the cost and availability in very few centres in our country. 
 
MAMMOGRAPHIC IMAGING SHOWING A MASS LESION IN RIGHT BREAST WITH 
MICROCALCIFICATION 
 
 PETCT IMAGES SHOWING DISTANT METASTASES 
Diagnostic Biopsy 
The final step and the most important step in triple assessment is 
the tissue diagnosis. The tissue diagnosis can be extracted through 
various techniques. Biopsy is considered to be superior to FNAC, as it 
can be run for receptor status too
19
. In case of impalpable lesion and 
accidentally detected tumours, imaging guided biopsy or FNAC is the 
choice of tissue sampling. 
FNAC has got a diagnostic accuracy 80% in breast carcinomas. In 
the hands of an experienced pathologist the false positive results are 
almost nil
19
. When false negative results are suspected and when the lump 
is clinically as well as radiologically suspicious, core biopsy or surgical 
excision is warranted. 
 
Core biopsy is the evaluation of choice in case of a solid mass and 
is performed either by palpation or by image guidance. In Stereotactic 
core biopsy the patient lies prone with breast suspended and compressed, 
the image is at an angle +/- 15 degree perpendicular to the and the 
coordinates are accurately marked. The biopsy gun is introduced through 
these marked sites and several biopsies are obtained and are imaged for 
microcalcifications
18,19
, a clip is placed at the biopsied site so post 
procedure exact region of specimen obtained can be demarcated. 
Ultrasound guided biopsy is easier and simpler than stereotactic 
biopsy as in shows a live demonstration of the biopsy to the radiologist or 
surgeon
16,19
. MRI guided biopsies are done for lesions which are only 
visible on MRI and needs vacuum assistance. 
In case of non-palpable lesions pre-operative localisation of the 
tumour is necessary and it aids the surgeon in complete excision and 
localisation during the intra operative period. The location of the lesion in 
mammography is varying as they are subjected to compression. A self 
retaining hooked wire is placed preoperatively either through 
mammogram and ultrasonography
19
. The site of location is traced intra-
operatively and excised completely with 1cm margin clearance and 
oriented to the pathologist. 
 HOOK TECHNIQUE FOR LOCALISATION 
  
Classification of breast carcinoma 
Breast carcinomas usually occupy the upper outer quadrant 
followed by central compartment and then equally by the lower 
quadrants. In 90% of the cases the carcinoma arises from the ductal 
epithelium and remaining from the lobular epithelium
20
. The 
classification is as follows. 
1. Non invasive (in situ) carcinoma 
- Intraductal carcinoma 
- Lobular carcinoma in situ 
2. Invasive carcinoma 
- Infiltrating(invasive) ductal carcinoma 
- Infiltrating(invasive) lobular carcinoma 
- Medullary carcinoma 
- Colloid carcinoma 
- Papillary carcinoma 
- Tubular carcinoma 
- Cribriform carcinoma 
- Secretory(juvenile) carcinoma 
- Inflammatory carcinoma 
- Carcinoma with metaplasia 
3. Paget’s disease of the nipple 
  
ULCERATIVE GROWTH OF LEFT BREAST 
 
FUNGATING GROWTH WITH METASTATIC DISEASE ON TABLE PICTURE OF 
TOILET MASTECTOMY 
Estrogen and progesterone receptors 
In 1960 a radiolabelled estrogen concentrations were studied and 
was observed that in breast carcinomas concentration percentage was 
significant and this led to the concept of estrogen and progesterone 
receptors
21
. ER α and β, PR A and B are primary estrogen and 
progesterone receptors. 
The estrogen and progesterone receptors have their effect in the 
nucleus by binding with hormones. In a normal breast both ER and PR 
exhibit positive nuclear immunostaining
21,22
, but heterogeneous in nature 
and tends to vary with each menstrual cycle. In comparison with ER 
patients who are PR positive tend to have longer duration of disease free 
interval
22
. 
 
ESTROGEN RECEPTOR MODEL 
The immunohistochemistry assay for hormonal receptors has 
become the gold standard in determining the ER and PR levels and has 
replaced the classical ligand binding assay which is also known as the 
dextran coated charcoal assay. In recent years with the development of 
quantitative reverse transcriptase polymerised chain reaction (qRTPCR)
23
 
,studies have proven that mRNA assay of ER and PR levels is a better 
method of determination. 
The advantages of IHC assay over dextran coated charcoal assay 
include the following 
• Histological documentation is available 
• Tumour nuclei cell heterogeneity can be made 
• Rapid turnaround time 
• Cost effective 
• Small size of sample is adequate 
• Can be reported directly visualised or by semi-quantitative 
methods 
  
The fundamental requirements for hormonal receptor assay by IHC 
method include the following 
• Formalin fixation of breast tissue with a time period of 8 – 72 
hours 
• 10% neutral phosphate buffered formalin is to be used 
• In-vitro diagnostic kits should be used which utilises the following 
6F11,1D5 or SP1 
• Controls should be used on each run 
• Semi quantified results should be based on the percentage of cells 
staining and their intensity of staining 
Recent studies have shown that in pre-analytic assay study 
minimum formalin exposure time for ER assessment is 8 hours
23
. With 
overexposed tissue antigen fixation is better but gradually decreases over 
a period of time. Meanwhile under-fixed tissue study is not worth the 
assay study. 
Conventional processor method is the choice of method for 
processing the tissue. Though alternate processor methods are available 
and widely used in many centres, the samples should be validated with 
that of the conventional processor methods. It’s mandatory to document 
the formalin exposure time and type of formalin used
24
. The antibodies 
used in common practise include 1D5, 6F11 and SP1 and are usually 
targeted against ERα. 
 Initially it was considered that even 1% of positive staining was 
reported as positive and adds the beneficial effect of tamoxifen therapy to 
patient. Several case control studies have proven the beneficiary effect of 
tamoxifen in high positive ER tumours have an overall survival rate is 
better compared to the placebo control group
25
. 
The Allred score quantifies the ER content in the tissue and studies 
have proven that there is a linear correlation between ER content and the 
allred score, more significant than reverse transcriptase PCR study. The 
tumour cells are reported as 0,1+,2+,3+ based on the intensity levels and 
are multiplied by and ordinal value and given the scoring system as : 
0 = none, 1= weak, 2 = moderate, 3 = strong  
The scoring ranges from 0 (no staining) – 300 (diffuse staining) 
Allred score = proportion score + intensity score 
The progesterone receptors are stained positive for PgR636 and 
PgR1294 compared to other receptors. The antibodies used in PR staining 
include the 1A6 and rabbit monoclonal antibody IE2. The ER and PR 
show parallel correlation and they hardly contradict when used with the 
same antibody. The IHC staining method in Progesterone receptors is 
more heterogeneous than estrogen receptors and show false negative 
results
23,24
. If there is any doubt or discrepancy in the results with core 
specimen, assay should be repeated with resection specimen 
 
 
 
  
ESTROGEN AND PROGESTERONE STATISTICAL 
DATA: 
• In general with data available from the south east Asian population 
the expression of estrogen receptor is around 50%
42
 . 
• The progesterone receptor positivity status is around 35% - 
45%
42,43
 . 
• The estrogen and progesterone positivity usually coexist together 
irrespective of the histological grading of the disease
43
 
• As the age advances the estrogen receptor positivity tends to 
increase. 
• The progesterone receptor positivity breast carcinomas usually tend 
to be larger in size compared to the other receptor positive 
statuses
44
.  
• As per CAP guidelines all receptors which show moderate 
positivity in allred score are considered positive universally
44
 
• When the ER positivity increases the HER2 positivity decreases 
• The commonest pattern of receptor status observed worldwide is 
ER+/ PR+/ HER2-
42,44,47
. 
• The study on recurrent metastatic breast carcinomas have revealed 
that there is conversion of receptor status
51
 
• If the patient is ER and PR receptor positive the disease free 
interval is better compared to ER+ and PR – ve tumors
44
 
• The IHC assay of hormonal receptors is considered superior to the 
classic ligand based assay
26
 
• In locally advanced breast carcinomas the progesterone positivity 
tends to be higher than the other receptors 
• ER and PR positivity is observed more in postmenopausal women 
than the other age group 
• Obesity tends to increase estrogen positivity
45
 
• Familial breast carcinomas are more in favour for ER+ and PR+ 
status 
 
 
 
 
 
 
 
 
HER2/neu 
The ERBB2 gene is called NEU as it was initially derived from rodent 
glioblastoma cell lines. Later it was named HER2 as it closes resembles 
the sequence of human epidermal growth factor receptor
25
. It contains a 
185kD glycoprotein molecular component with tyrosine kinase activity. 
 
MECHANISM OF HER2 GEME AMPLIFICATION MODEL 
 
 
About 15-20% of the breast cancer cells demonstrate 
overexpression or HER 2 gene amplification. HER2 positive tumours 
benefit from taxanes and anthracycline based therapies, they are less 
responsive to other hormonal therapies. A humanised monoclonal  
antibody, trastuzumab is effective against HER2 gene expression and 
improves the survival, time of progression and response rate compared to 
other drugs
31
. 
As per the new guidelines formulated by ASCO/CAP all newly 
detected invasive breast carcinomas should be checked for HER2 status 
as they play an important role in further management of breast 
carcinoma
28
.The prognostic value in breast carcinoma is dependent on the 
following factors 
• Tumor size 
• Type of tumor – histology 
• Lymphatic involvement 
• ER and PR status 
• HER2 status 
• Nuclear grade  
• Mitotic activity 
 
According to CAP guidelines the tissue is to be paraffin embedded 
and 10% neutral buffered formalin fixed for at least 6 hours. Over - fixed 
tissue can give difference in interpretation but under-fixed tissue usually 
gives false negative test
29
. Though different methods of fixation are 
available, each of them have to be compared with the standard protocol. 
The antibodies CB11 and 4D5 are used to determine HER2 status. 
4B5 a newly developed rabbit monoclonal antibody is available for better 
determination for HER2 status
30
. The HER2 IHC is interpreted as follows 
• 0(negative) – no staining / < 10% membranous staining in tumor 
cells 
• 1+(negative) – barely precipitated staining in >10% of tumor cells 
• 2+(equivocal) – weak to moderate complete staining in > 10% of 
tumor cells 
• 3+(positive) – strong complete membrane staining in >30% 
oftumor cell 
 
All 2+ IHC cells are subjected to FISH for confirmation. 
 
  
FISH in HER2/NEU 
This technique uses molecular cytogenetics as basis and requires 
special fluorescent probes to detect DNA sequences in chromosomes. The 
probe identifies gene amplification. It comes as either single or dual 
coloured probes with sequences labelled for HER2 and the other for CEP 
17 (chromosome 17 centromere)
29
. The single probe detects gene 
amplification, whereas the dual probe measures the ratio of HER2 to that 
of CEP17. 
HER2 gene is unique in its gene amplification sequencing and is 
tightly bound to the protein which is characteristic to this in particular and 
differentiates it from other genes
30
. In case of dual probes which 
measures the ratio the cut off mark has been set by standard guidelines 
which include the following. 
• <1.8 – negative 
• 1.8 – 2.2 – equivocal 
• >2.2 – positive 
 
 
 
In case of single colour probe which determines the gene 
amplification the scores are fixed as following 
• HER2 <4 – negative 
• HER2 4-6 – equivocal 
• HER2 >6 – Positive 
Studies have proven that FISH is a better predictor of HER2 
compared to IHC. The assay is to be preferably performed in resection 
specimens than core biopsies. 
The Limitations of FISH include the following 
• Morphological features are not distinct 
• Need for dark field fluorescenct microscopy 
CISH (chromogenic in situ hybridisation) makes use of DAB 
(diamino – benzidine)as chromogen for signalling and has gained recent 
popularity but still less accepted as it uses bot IHC as well as cytogenetic 
theories and has difficulty in interpretation
29,31
. 
In order to overcome the demerits of CISH, SISH ( silver in situ 
hybridisation) is developed and it deposits silver ions to target cells by the 
use of enzyme linked probe and simplifies the procedure with easy 
identification of ions
32
. Owing to change in the modality of treatment 
according to HER2 reports. HER2/NEU is considered to be the single 
most important theranostic predictor in breast carcinoma. 
The other tumor markers employed in breast carcinoma include the 
following 
• p53 
• ki-67 
• EGFR 
• uPA and PAI- 1 
• FOXA 1 
• GATA 3 
 
 
  
HER2 STATISTICAL DATA: 
• In receptor status the single most important prognostic factor is the 
HER2 expression 
• The HER2 positivity is usually high in high grade tumors
50
 
• The HER2 positivity often shows a decrease in expression with 
advancing age
43
 
• Overall 25 of all breast carcinomas overexpress HER2 irrespective 
of the stage of the disease
46,48
 
• In recurrent metastatic breast carcinomas the conversion of HER2 
positivity to negative status has been observed which denotes poor 
survival significance
51
. 
• As per CAP guidelines the recommended assay is FISH in case of 
HER2 2+ positive tumors by IHC
26
 
• The surrogate classification of hormonal receptors is universally 
accepted combination pattern
48,49
 
• As per the present data available no data had concluded that triple 
negative tumors have a similar survival pattern as compared to the 
other surrogate classification of hormonal receptors
48,50
. 
 
  
BRCA 1 AND 2: 
BRCA 1 and BRCA 2 are located in the long arm of chromosome 
17 and 13 respectively. They are considered to be cancer susceptible 
genes and are responsible for familial breast cancer. This tumor 
suppressor gene has autosomal dominant mode of inheritance and causes 
germ line mutation in the allele and predisposes every cell to cancer 
development
33
. 
Unlike BRCA 1 the BRCA 2 predisposes the patient to ovarian 
malignancies. And any male breast carcinoma warrants a familial check 
on BRCA 2 as it predisposes to male breast carcinomas too. BRCA 2 
positive tumors are usually HR negative, aneuploidy, high grade and 
show increased S phase fraction. 
BRCA 1 and 2 positive patients are considered to be high risk in 
view of development of breast carcinoma and recent studies have proven 
prophylactic mastectomy to be effective and reduce the risk of by a great 
deal
33
. 
 
 
  
MANAGEMENT OF EARLY BREAST CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triple assessment test 
Early breast carcinoma 
-chest x ray 
-LFT 
-USG abdomen 
-ER/PR/HR status receptors 
Candidate for breast conservation 
yes no 
Breast conservation 
therapy 
Modified radical 
mastectomy 
4 or more positive nodes ER positive 
Tumour > 1 cm  
Age <70 years 
Chemotherapy followed by 
radiotherapy 
tamoxifen chemotherapy 
MANAGEMENT OF LOCALLY ADVANCED BREAST 
CARCINOMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triple assessment test 
Locally advanced breast 
carcinoma 
-chest x ray 
-LFT 
-USG abdomen 
-ER/PR/HR status receptors 
-Bone scan 
 
Neoadjuvant chemotherapy 
Complete or 
partial response 
Non responder 
Breast 
conservation/ 
MRM 
chemotherapy 
radiotherapy 
inoperable operable 
Surgery/MRM 
Radiotherapy/ 
hormonal 
therapy 
MANAGEMENT OF METASTATIC BREAST 
CARCINOMA 
 
 
 
Modified radical mastectomy 
In case of T1 - T3 lesions skin sparing mastectomy is performed in 
which the nipple areolar complex with the breast tissue and 1 cm of skin 
around the excised scar is removed. The simple mastectomy involves the 
removal of the nipple areolar complex, entire breast tissue and the 
necessary skin. Extended simple mastectomy involves the removal of 
level I lymph nodes along with the other structures listed in simple 
mastectomy. The modified radical mastectomy involves removal of all 
the breast tissue with nipple areolar complex, necessary skin and the level 
I and II lymph nodes
34
.Patey modified MRM with removal of pectoralis 
minor muscle and level III lymph nodes. Halsted’s mastectomy included 
removal of pectoralis major along with other structures, but current 
advances with radiotherapy and hormonal therapy, this concept is almost 
eliminated.  
The patient is positioned supine with ipsilateral shoulder elevated 
in order to aid movements while performing the procedure. The 
ipsilateral arm is either fixed or rolled with stockinette to mobilise the 
arm during axillary dissection. 
 
 
  
STRUCTURES TO BE PRESERVED IN MODIFIED RADICAL MASECTOMY 
 
The skin incision is placed in such a way that the tumour is 
removed as an enbloc specimen with nipple areolar complex with 
overlying skin and skin margins clearance of 1 to 2 cm cephalad and 
caudad. The common incisions placed include the Stewarts and Orr’s of 
which each has slight modifications to include adequate clearance
36
. 
 
STEWART’S INCISION 
 
 
 
ORR’S OBLIQUE INCISION 
 
 
 
The skin flaps are raised exposing the anterior margin of latissimus 
dorsi laterally, sternum medially, subclavius muscle superiorly and rectus 
muscle inferiorly.The plane of dissection should be deep to the 
subcutaneous vasculature and superficial to the breast tissue in order to 
avoid flap necrosis and seroma formation. The breast tissue is dissected 
along with the pectoralis fascia starting from medial boundary until 
pectoralis minor is exposed. Care is taken not to injure the medial 
pectoral nerve as it causes atrophy of the pectoralis major muscle. 
The axilla is entered by dividing the investing fascia and interpectoral 
(rotter’s nodes) lymph nodes are cleared. Later by dividing the loose 
areolar tissue the lateral extent of axillary vein lying antero-inferiorly to 
the axillary artery and brachial plexus is identified
35,36
. The fascia over 
the anteroventral surface of the axillary vein is sharply dissected exposing 
the level I and II lymph nodes. 
The thoracodorsal bundle is located deep in the axillary space and 
invested by loose areolar tissue. The thoracodorsal nerve originates from 
the posterior cord and supplies the latissimus dorsi muscle. The loose 
areolar tissue surrounding the thoracodorsal bundle is dissected by medial 
retraction of the lateral nodes and removed in enbloc along with 
subscapular group of lymph nodes
34,35,36
. 
  
INTROP PICTURE SHOWING ASILLARY DISSECTION 
 
Dissection is further continued exposing the posterior contents of 
axilla and later medially removing the central group of lymph nodes. The 
superomedial limit of axillary dissection is marked with a stapler for 
pathological orientation. In the medial aspect of axilla, chest wall is 
exposed and nerve to serratus anterior is encountered, which lies in front 
of the subscapularis muscle. 
 In patey’s modification the tendinous portion of the pectoralis 
muscle is removed to aid in clearance of level III lymph node. Thorough 
saline lavage is give and haemostasis is secured. Axillary and flap drains 
are placed separately and fixed. Skin is approximated in layers. Drains 
are retained till the collection is < 30ml/24 hours for 2 days.  
 
 
MODIFIED RADICAL MASECTOMY SPECIMEN EXCISED IN TOTO 
 
  
The possible complications post mastectomy include 
36 
1. Seroma (30%) 
2.  Wound infection 
3.  Bleeding 
4.  Flap necrosis  
5.  Lymphedema 
6.  Intercostobrachial nerve injury (numbness of medial aspect of upper 
arm) 
7.  Long thoracic nerve injury (winged scapula) 
8.  Medial and lateral thoracic nerve injury (Pectoralis muscle atrophy) 
9.  Thoracodorsal nerve injury (internal rotation and abduction of 
shoulder) 
 
 
 
 FLAP NECROSIS 
 
 
 
 
 
 
 
SENTINEL LYMPH NODE BIOPSY 
 
       Sentinel lymph node is considered to be the first lump node 
encountered by the primary tumour, and owing to its histological status 
the lymph basin involvement of a metastatic disease can be predicted
37
. 
Intra-operatively the node is excised and sent for frozen section biopsy 
and its involvement is studied. 
             A clinically T1 or T2 disease without any lymphadenopathy 
warrants a sentinel lymph node biopsy before proceeding to axillary 
dissection. The agents used include technetium
99 
labelled colloid albumin 
and isosulfan vital blue dye which is given either as subdermal / 
peritumoral / intratumoral injections. 
 
 
The dye is given either the day prior to surgery or on table and the 
uptake is picked up by a gamma probe and frozen sectioning is done
37
. 
The advantages of sentinel lymph node biopsy include the following 
• Cost effective 
• Minimally invasive technique 
• Micro-metastasis can be studied better 
• Can avoid axillary dissection 
The disadvantages include 
• Skip metastasis is possible 
• Not useful for stage IIB lesions 
  
SERM 
Selective estrogen receptor modulators have antagonistic and 
agonistic activity in different tissues in the body. They compete in 
occupying the receptor space in breasts and reduce the binding coefficient 
of estrogen in breast tis
uterine receptors. The main use of tamoxifen is its use in ER positive 
breast tumours and metastatic breast disease. Tamoxifen is orally 
absorbed and metabolised by CYP450 and is excreted in bile
The adverse effects include hot flushes, nausea, vomiting and has 
the potential to develop endometrial cancer in long standing cases.
 
 
sue. Meanwhile they have an agonistic action in 
MECHANISM OF ATION OF SERM 
 
38
. 
 
 
TRASTUZUMAB
Around 25 -
receptor. Trastuzumab
technology targeted specifically against these receptors. It decreases the S 
phase growth of tumour cells by inhibiting the cellular proliferation, the 
other possible hypothesis include antibody mediated cytot
regulation by its effect on angiogenesis
Trastuzumab is available as IV formulation and should be carefully 
administered in patient with cardiac dysfunction as it has a potency to 
develop heart failure. The cardiac complication of this d
the drug is combined with anthracyclines
MECHANISM OF ACTION OF TRASTUZUMAB
 
 
 30% of breast malignancies overexpress the HER2 
 is a monoclonal antibody with DNA recombinant 
39
. 
rug is worsened if 
39
. 
 
oxicity or down 
 
CHEMOTHERAPY 
The indications for chemotherapy include the following. 
• Locally advanced breast carcinoma and metastatic 
• Node positive status 
• Triple negative cases 
• HER2 positive cases 
• Size >0.5cm and less than 70 years of age 
The new concept of breast malignancy is that it a systemic disease 
from the very beginning and in order to tackle the micrometastasis 
chemotherapy is indicated
40
. The common regimen used is 
cyclophosphamide, adriamycin and 5 -fluorouracil. 
  
PAGET’S DISEASE OF THE NIPPLE: 
This condition is associated with destruction of the nipple, as it is 
superficial involvement of intraductal carcinoma. It is a close mimicker 
of nipple eczema and needs to be differentiated by tissue biopsy. They 
contain paget’s cells filled with mucopolysaccharides located in retepegs 
of epidermis. 
       They usually present with an underlying lump and more than 90% of 
them are proven to be invasive ductal carcinoma. This condition warrants 
modified radical mastectomy 
 
 
PAGETS DISEASE OF THE NIPPLE 
 
 
FOLLOW UP 
The chance of recurrence is more within the first 5years of 
treatment for carcinoma breast and should be under follow up 20 years 
post treatment. As per international guidelines all patients who undergo 
treatment for breast carcinoma should be followed up as per this protocol 
• Every 4 months for first 2 years 
• Every 6 months for third to fifth year 
• Every yearly thereafter 
-Chest x-ray and mammogram are done yearly 
-Bone scan, CT chest/ abdomen and brain are done if warranted clinically 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
MATERIALS 
 A Prospective study conducted in PSG Institute of Medical 
Sciences and Research comparing the ER/PR/HER2 status in different 
stages of breast carcinoma in 30 patients 
QUESTIONNAIRE 
NAME: 
AGE: 
SEX: 
IP NO: 
OP NO: 
DOA: 
 
HISTORY (ONSET, DURATION AND SITE): 
PAST/PERSONAL/MARITAL AND MENSTUAL HISTORY IF 
RELEVANT: 
 
PHYSICAL EXAMINATION (SIZE, NODAL STATUS AND 
METASTATIC DISEASE FINDINGS): 
MAMMOGRAM/USG BREAST: 
 
FNAC/BIOPSY: 
 
CXR,LFT,USG ABDOMEN & PELVIS: 
 
MRI/PET (if any): 
 
NEOADJUVANT CHEMOTHERAPY (if any) 
 
SURGERY PLANNED: 
 
HISTOPATHOLOGY REPORTS: 
 
ER/PR/HRSTATUS: 
 
  
INCLUSION CRITERIA: 
• Women of all age groups 
• Biopsy/FNAC proven Carcinoma Breast  
• Bilateral involvement 
• Any stage 
EXCLUSION CRITERIA: 
• Suspicious benign breast diseases 
• Male breast carcinoma 
• Phyllodestumour 
METHODOLOGY: 
In this study 30 patients were divided and sub – categorised into 
early, late and metastatic breast carcinoma after clinical examination, 
each containing a group of 10. Informed consent was obtained detailing 
the study process, need for the study and its benefits, elaborately. The 
history was recorded by the principal investigator and the mode of 
presentation (lump, pain, nipple discharge/retraction), duration and 
progression. Family and past history of any breast or gynaecological 
malignancies were enquired in detail. 
All 30 patients were subjected to clinical examination by the 
principal investigator and to avoid bias the patient was re-examined by a 
faculty member and clinical TNM staging of the disease was formulated.  
Triple assessment was done for all 30 patients and categorisation 
was confirmed naming them as early breast carcinoma, locally advanced 
breast carcinoma and metastatic breast carcinoma. They were subjected to 
either trucut biopsy or in case of FNAC proven malignancy – Modified 
radical mastectomy was done and resected specimen was assayed for 
ER/PR and HER2. 
All patients underwent metastatic workup with liver function test, 
chest x ray, ultrasonography of the abdomen and in suspicious cases of 
metastatic disease the patients were subjected to PETCT/ MRI / Bone 
scan for further disease spread. 
In all 30 patients Immunohistochemistry assay was carried out in 
the specimen in our NABH accredited lab and reported as per standard 
Allred scoring system and CAP guidelines. In case of HER 2+ status, 
FISH was not carried out due to non-availability.  
The patients underwent either surgery, radiotherapy, hormonal 
therapy, neoadjuvant /adjuvant chemotherapy depending on the staging of 
the disease. All the above details elicited and investigated were uniformly 
done in the same imaging and pathological set up to avoid bias. All the 
details are documented in a questionnaire format and confidentially 
preserved with the principal investigator of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
RESULTS AND OBSERVATIONS 
 
  
OBSERVATION 
ANALYSIS OF DATA 
• Total of 30 cases were included in this study 
• They were sub- categorised into early breast carcinoma, locally 
advanced breast carcinoma and metastatic breast carcinoma. 
• As a prognostic indicator the various combinations of ER, PR and 
HER2 are categorised as follows
46
 
GOOD 
• ER+   PR+    Her2− 
• ER−   PR+    Her2− 
• ER+   PR−    Her2− 
MODERATE 
• ER+  PR+  Her2+  
• ER−   PR+  Her2+  
• ER+   PR−  Her2+ 
POOR 
•  ER−  PR−   Her2+ 
• ER−  PR−   Her2− 
 
 • All the 30 patients were systematically worked up with triple 
assessment and receptor status and were documented after 
obtaining informed consent. 
DATA ANALYSIS 
Data collected were entered in Excel Spread sheet and analysed 
using STATA statistical software package release 11. We used the two-
sided independent-samples t test to compare means across dichotomous 
variables (i.e. men v. women); the one-way ANOVA test for comparison 
of means across multilevel variables. Pearson’s Correlation analysis was 
done and correlation coefficient was derived. Simple calculations like 
Percentages, Proportions and Mean values were derived. A type I error of 
0.05 was considered in all analyses. 
 
 
 
 
 
  
  EBC 
Mean 
Age 
51.6 ± 
7.1 
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AGE DISTRIBUTION 
LABC Metastatic P Value 
52.7 ± 
17.3 
56.6 ± 
12.5  >0.05 
LABC
MEAN AGE
 
Metastatic
 Age in 
years EBC
<30 0 
30 - 39 0 
40 - 49 4 
50 - 59 4 
60 - 69 2 
70 - 79 0 
80+ 0 
Total 10 
0
1
2
3
4
<30
N
Age wise distribution of different Stages
 LABC METASTATIC 
1 0 1 
2 1 3 
2 2 8 
1 3 8 
3 2 7 
0 2 2 
1 0 1 
10 10 30 
30 - 39 40 - 49 50 - 59 60 - 69 70 -
EBC LABC METASTATIC
 
Total 
79 80+
 • In this study the youngest patient was 28 years and the oldest 
patient was 82 years. The mean age was 53.6 years. 
• Early breast carcinoma was predominantly occupying the 4
th
 to 6
th
 
decade. 
• Locally advanced breast carcinoma had a wide distribution of age 
group from the youngest to the oldest patient. 
• Metastatic carcinoma shows an increasing trend as the age 
advances. 
• More than 80% of the patients were between 40 to 70 years of age. 
 
 
 
 
  
DISTRIBUTION OF TYPES OF CARCINOMA
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Type of carcinoma EBC LABC Metastatic Total 
Apocrine carcinoma 0 1 1 2 
Infiltrating ductal carcinoma 9 8 7 24 
Invasive lobular carcinoma 0 1 0 1 
Invasive papillary carcinoma 0 0 1 1 
Poorly differentiated squamous 
cell carcinoma 
0 0 1 1 
mixed invasive and mucinous 
carcinoma 
1 0 0 1 
Total 10 10 10 30 
 
• The most common type of carcinoma is the infiltrating ductal 
carcinoma. 
• The IDC occupies 80% of the study population. 
• Predominant metastatic carcinomas also belong to IDC variety. 
• A rare variety of poorly differentiated of squamous cell carcinoma 
of the breast is also encountered in our study which showed 
metastatic disease.  
• One patient had mixed invasive and mucinous carcinoma. 
• Medullary carcinoma, Colloid carcinoma, Tubular carcinoma, 
Cribriform carcinoma were not encountered in the study group. 
 
ER, PR AND HER2 STATUS 
  
0
1
2
3
4
5
6
7
8
<30
N
Age wise positivity in ER, PR & HER2 positivity
 
30 - 39 40 - 49 50 - 59 60 - 69 70 
ER PR HR
 
- 79 80+
 Age in 
years 
ER 
Positivity 
PR 
Positivity 
HER2 
Positivity 
<30 0 0 1 
30 - 39 1 1 1 
40 - 49 3 2 8 
50 - 59 4 2 5 
60 - 69 6 3 4 
70 - 79 0 0 1 
80+ 1 0 1 
Total 15 8 21 
 
• Among 30 patient inclusive of all stages of carcinoma only 
50% showed estrogen receptor positivity 
• 70% of the study population showed HER2 positivity 
irrespective of the clinical staging. 
• In this study group progesterone receptor positive status was 
seen only in 8 patients which is only 26.6% 
• All 3 receptors namely ER/PR and HER2 showed their 
predominance in the age group between 40-70 years 
 
EARLY BREAST CARCINOMA
 
 
• In early breast carci
• Only 30% showed PR positivity
• 70% of Early breast carcinomas showed HER2 positivity
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LOCALLY ADVANCED BREAST CARCINOMA
 
 
• 60% of LAB carcinomas showed ER positivity
• PR was positive only in 30% of Locally advanced breast 
carcinomas 
• Only 2 patients were negative for HER2 in Locally advanced 
breast carcinomas
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METASTATIC BREAST CARCINOMAS
 
• 40% of the metastatic tumors were ER positive
• Only 20% of metastatic breast carcinomas exhibited PR positivity
• HER2 was significantly 
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positive in 60% of this study population
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INCLUSIVE OF 3 DIFFERENT STAGES
 
 
Negative
EBC 50%
LABC 40%
Metastatic 60%
Total 50%
 
0%
10%
20%
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80%
Negative 
ER
COMBINED STATISTICS 
ER PR 
 Positive Negative Positive Negative
 50% 70% 30% 30%
 60% 70% 30% 20%
 40% 80% 20% 40%
 50% 73.33% 26.67% 30%
Positive Negative Positive Negative Positive
PR HR
Total
 
 
HER 
 Positive 
 70% 
 80% 
 60% 
 70% 
CORRELATION BETWEEN DIFFERENT RECEPTORS 
 
ER PR HER 
ER & 
PR 
ER & 
HER 
PR & HER 
 
Positive Positive Positive 
P 
Value 
P 
Value 
P Value 
EBC 50% 30% 70% >0.05 >0.05 >0.05 
LABC 60% 30% 80% >0.05 >0.05 <0.05 
Metastatic 40% 20% 60% >0.05 >0.05 >0.05 
Total 50% 26.67% 70% 
   
 
  
  
The combined statistical data analysis of all 30 in the study group
show the following
• Overall 50% of patients have ER positivity
• PR positivity is seen only in 26.67% of the study population
• HER is positive in 70% of the study population
0%
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40%
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70%
80%
EBC
Distribution of ER, PR & HR Positivity according to 
 
 
 
LABC
Different Clinical Stages
ER PR HR
 
 
 
Metastatic
• The p value of comparison of different results with one another 
show significance for comparison of PR and HER2 status in locally 
advanced carcinomas. 
 
As mentioned above after categorising the ER,PR and HER2 
prognostic significance and combination as good, moderate and poor in 
different stages the results obtained are as follows 
 
stage Hormonal prognostic predictors 
 
Good moderate poor 
EBC 5 5 0 
LABC 6 3 1 
Metastatic 4 3 3 
 
 
  
• Early breast carcinoma has no patients in worst prognostic category 
of hormonal receptors 
• In Locally advanced breast carcinoma 10% of the population fall 
under bad prognostic category 
• 30% of metastatic carcinomas have bad prognostic index category 
• Overall 50% of the patients fall under good hormonal prognostic 
index irrespective of the stage of disease 
• 11 out of 30 patients fall under moderate prognostic criteria 
• Only 13.3% of patients fall under poor prognosis category 
• All 3 patients in metastatic disease with poor prognostic predictor 
had triple negative results 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
A prospective case study of estrogen, progesterone and 
Human epidermal growth factor 2 receptor status in different 
stages of breast carcinoma was studied in 30 patients and the study 
infers the following 
This study expands the information available from prior research 
by assessing breast cancer staging with that of ER/PR/HER2 subtypes 
and we have concluded our experience in the study population which 
exhibits particular similarities and differences compared to that of 
international research data available 
• The most common type of malignancy in the study group is 
invasive ductal carcinoma which is on comparison with 
international data
20
 
• The mean age of the study group is 53.6 and is almost equal 
to the study conducted in south-indian population
43
. 
• 80% of the study population lie within 40 – 70 years age 
group and more in the peri-menopausal age group
43,44
 
• The p value comparison of different results with one another show 
significance for comparison of PR and HER2 status in locally 
advanced carcinomas 
 
 
• None of the early breast carcinomas showed poor hormonal 
prognostic index and is in disjunction compared to 
international studies
46,48
. 
• 30% of metastatic population had associated poor hormonal 
prognostic predictor and is correlating with the previous data 
available
46,47
 
• HER2 was positive in 70% of the population which 
outnumbered the other hormonal receptors, whereas only 
25% of the breast carcinomas overexpress HER2 
universally
50
 
• There is no specific pattern of hormonal receptors 
association in any of the particular stage which is different 
from the data available as most of the early breast 
carcinomas express ER and PR positivity
44
 
• The overall progesterone receptor status positivity is only 
26.66% which is far less compared to usual pattern in Indian 
population which is around 63%
42,43
 
• There is no significant coexisting positivity status between 
estrogen receptor and progesterone receptor which is unusual 
as they usually express similarity pattern
48,49
 
 
• All 3 patients (10% overall) in metastatic group had triple 
negative disease which is in conjunction with international 
data
46,47,50
 
• Correlation Model between prognosis according to clinical and 
hormonal staging shows a positive correlation with correlation 
coefficient of 0.2659 with significance of >0.05 (overall) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CONCLUSION 
  
CONCLUSION AND RECOMMENDATIONS 
Hormonal therapy plays an important role in the management of 
breast carcinomas in the recent era and adds on to benefit the patient. It is 
also an important prognostic index for the disease progression and is now 
mandatory that all diagnosed patients of breast carcinoma should undergo 
hormonal receptor assay. 
This studyshows the following similarities and variations compared 
to international data available.In our study ER reactivity was seen 50% 
and PR reactivity 26.67% of breast cancers whereas in a similar study 
conducted at the Liaquat national hospital, Karachi, Fatima et al (2005) 
showed 55% ER and PR reactivity.In this study we experienced 70% 
positivity which is grossly high compared to international data which 
shows only 25% positivity. Out of the four triple negative tumors 
encountered in this study 3 were belonging to metastatic group and all 
were histologically high grade which is in conjunction with the 
international data
50
. There is usually a coexisting pattern of expression 
between ER and PR which is not observed in this study
49
.In early breast 
carcinomas the HER2 positivity is usually less but in our study we have 
experienced 70% positivity which is significantly high. 
 
The study does have its own limitations due to a small sample 
number, selective sampling, interpreter variation and non-availability of 
FISH technique, but the limitation is overcome by extensive comparison 
standards and correlation with international data. 
Herewith we conclude our overall experience studying the 
estrogen, progesterone and HER2 receptor in different stages of breast 
carcinoma in 30 patients and the study shows a significant positive 
correlation between the hormonal status and clinical staging overall. 
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APPENDIX 
 
  
PROFORMA 
 
QUESTIONNAIRE 
NAME: 
AGE: 
SEX: 
IP NO: 
OP NO: 
DOA: 
 
HISTORY (ONSET, DURATION AND SITE): 
PAST / PERSONAL / MARITAL AND MENSTUAL HISTORY IF 
RELEVANT: 
PHYSICAL EXAMINATION (SIZE, NODAL STATUS AND 
METASTATIC DISEASE FINDINGS): 
MAMMOGRAM/USG BREAST: 
FNAC/BIOPSY: 
CXR,LFT,USG ABDOMEN & PELVIS: 
 MRI/PET (if any): 
NEOADJUVANT CHEMOTHERAPY (if any) 
SURGERY PLANNED: 
HISTOPATHOLOGY REPORTS: 
ER/PR/HRSTATUS: 
 
 
 
 
 
  
MASTER CHART 
STAGE ER PR HR TYPE OF CARCINOMA AGE 
EBC negative negative positive Infiltrating ductal carcinoma 50 
EBC negative negative positive Infiltrating ductal carcinoma 49 
EBC positive negative positive Invasive ductal carcinoma 42 
EBC positive negative negative Invasive ductal carcinoma 60 
EBC negative negative positive Infiltrating ductal carcinoma 55 
EBC positive positive negative Infiltrating ductal carcinoma 55 
EBC negative negative positive Infiltrating ductal carcinoma 43 
EBC negative negative positive Infiltrating ductal carcinoma 45 
EBC positive positive negative mixed invasive and mucinous cacinoma 63 
EBC positive positive positive Infiltrating ductal carcinoma 54 
LABC positive negative positive Infiltrating ductal carcinoma 83 
LABC positive positive positive Infiltrating ductal carcinoma 40 
LABC positive negative negative Apocrine carcinoma 38 
LABC negative negative positive Infiltrating ductal carcinoma 49 
LABC positive negative positive Invasive ductal carcinoma 66 
LABC positive positive positive Invasive ductal carcinoma 67 
LABC positive negative negative Invasive ductal carcinoma 54 
LABC positive positive positive Infiltrating ductal carcinoma 37 
LABC negative negative positive Invasive ductal carcinoma 28 
LABC negative negative positive Invasive lobular carcinoma 65 
METASTATIC positive negative positive Invasive papillary carcinoma 53 
METASTATIC negative negative negative 
Poorly differentiated squamous cell 
carcinoma 
76 
METASTATIC positive positive negative Infiltrating ductal carcinoma 62 
METASTATIC negative negative positive Infiltrating ductal carcinoma 55 
METASTATIC negative negative negative Infiltrating ductal carcinoma 53 
METASTATIC negative negative positive Infiltrating ductal carcinoma 48 
METASTATIC negative negative positive Invasive apocrine carcinoma 75 
METASTATIC negative negative negative Infiltrating ductal carcinoma 37 
METASTATIC positive negative positive Infiltrating ductal carcinoma 62 
METASTATIC positive positive positive Infiltrating ductal carcinoma 45 
 
